Hospital
Bellin Memorial Hospital INC.
Bellin Memorial Hospital INC. was paid $29.28M by Medicaid between Jan 2018 and Dec 2024, across 437 billing codes. Its largest line is 99283, emergency room visit (moderate) — 6.0% of everything it billed.
33Billing provider infoBELLIN MEMORIAL HOSPITAL INC.
GREEN BAY, WI 54301
GREEN BAY, WI 54301
33aNPI1891740585assigned 05/23/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$29.28M
24GClaims1,540,476
24DCodes billed437
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 174,526 | $3.47M | |
| 2019 | 187,099 | $3.50M | |
| 2020 | 199,407 | $3.65M | |
| 2021 | 253,329 | $4.84M | |
| 2022 | 255,720 | $4.99M | |
| 2023 | 252,700 | $4.73M | |
| 2024incomplete | 217,695 | $4.10M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.0% | 31,589 | 27,629 | $1.74M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.4% | 24,018 | 21,288 | $1.59M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.5% | 28,363 | 23,740 | $1.31M |
| 80053 | Comprehensive metabolic panel | 4.4% | 65,100 | 50,772 | $1.28M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.8% | 3,786 | 3,343 | $1.13M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.4% | 22,990 | 20,213 | $998K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.2% | 15,764 | 12,080 | $934K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.1% | 9,129 | 6,180 | $896K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.7% | 15,336 | 13,693 | $797K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.6% | 12,923 | 11,349 | $773K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.3% | 14,779 | 11,916 | $682K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 8,867 | 7,735 | $589K |
425 more codes
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.0% | 18,484 | $577K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.7% | 18,489 | $503K |
| 87631 | 1.7% | 4,509 | $497K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 7,531 | $449K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.5% | 5,964 | $439K |
| G0378 | Hospital observation service, per hour | 1.5% | 18,024 | $438K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.5% | 2,210 | $432K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 65,660 | $413K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.3% | 9,221 | $392K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.2% | 16,693 | $352K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 4,072 | $310K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,422 | $282K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 11,621 | $277K |
| 99285 | Emergency room visit (most serious) | <1% | 4,875 | $277K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 6,691 | $264K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 23,148 | $247K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 8,083 | $245K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,645 | $231K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,905 | $228K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 4,117 | $225K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,026 | $221K |
| 87507 | <1% | 764 | $219K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 12,829 | $216K |
| 87081 | <1% | 17,750 | $197K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,966 | $194K |
| 82962 | <1% | 22,808 | $192K | |
| 43248 | <1% | 1,058 | $181K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,746 | $169K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,912 | $166K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,628 | $158K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,157 | $157K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 7,353 | $150K |
| 43235 | <1% | 774 | $148K | |
| 80061 | Lipid panel | <1% | 13,054 | $147K |
| 81025 | <1% | 13,230 | $141K | |
| 80050 | General health panel | <1% | 5,282 | $140K |
| 82607 | <1% | 11,591 | $132K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,710 | $129K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 2,131 | $128K |
| 84484 | <1% | 16,383 | $126K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,121 | $122K |
| 81001 | <1% | 29,919 | $122K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 2,043 | $119K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 172 | $119K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 305 | $119K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 10,224 | $118K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,160 | $118K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,456 | $116K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,385 | $112K |
| 62323 | <1% | 846 | $111K | |
| 58661 | <1% | 68 | $109K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,169 | $109K |
| 83880 | <1% | 4,807 | $100K | |
| 97597 | <1% | 2,222 | $94K | |
| 86803 | <1% | 7,804 | $91K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 931 | $87K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,616 | $83K |
| 96367 | <1% | 2,230 | $80K | |
| 82728 | <1% | 8,058 | $80K | |
| 83690 | <1% | 14,474 | $79K | |
| 84702 | <1% | 4,340 | $72K | |
| 83655 | <1% | 5,986 | $72K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,777 | $72K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,364 | $70K |
| 86618 | <1% | 5,010 | $68K | |
| 76642 | <1% | 1,734 | $67K | |
| 58571 | <1% | 39 | $67K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 202 | $65K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 5,023 | $64K |
| 86780 | <1% | 6,962 | $64K | |
| 93971 | <1% | 2,139 | $63K | |
| 84439 | <1% | 7,853 | $62K | |
| 82746 | <1% | 5,785 | $61K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,395 | $58K |
| 87186 | <1% | 8,556 | $56K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,258 | $56K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 231 | $55K |
| 86900 | <1% | 4,956 | $54K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,415 | $53K |
| 93017 | <1% | 1,512 | $53K | |
| 84403 | <1% | 2,372 | $53K | |
| 86480 | <1% | 995 | $52K | |
| 84466 | <1% | 5,920 | $52K | |
| 87340 | <1% | 6,286 | $52K | |
| 85610 | <1% | 10,202 | $51K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,756 | $50K |
| 95806 | <1% | 560 | $50K | |
| 87150 | <1% | 1,701 | $49K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,542 | $47K |
| 85379 | <1% | 6,409 | $45K | |
| 88341 | <1% | 3,094 | $44K | |
| 87077 | <1% | 3,878 | $44K | |
| 93296 | <1% | 2,488 | $43K | |
| 86850 | <1% | 4,718 | $43K | |
| 86762 | <1% | 3,373 | $43K | |
| 30140 | <1% | 39 | $43K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,934 | $42K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,972 | $42K |
| 83516 | <1% | 3,434 | $41K | |
| 87641 | <1% | 1,328 | $39K | |
| 85027 | <1% | 6,549 | $39K | |
| 86140 | <1% | 8,180 | $38K | |
| 83735 | <1% | 9,921 | $38K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 623 | $37K |
| 87088 | <1% | 3,787 | $37K | |
| 83605 | <1% | 5,327 | $36K | |
| 87070 | <1% | 3,506 | $36K | |
| 76770 | <1% | 598 | $35K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 597 | $32K |
| 83540 | <1% | 6,729 | $31K | |
| 82565 | <1% | 2,661 | $30K | |
| 71250 | <1% | 957 | $30K | |
| 83970 | <1% | 1,027 | $29K | |
| 86038 | <1% | 3,039 | $29K | |
| 84703 | <1% | 2,872 | $28K | |
| 82784 | <1% | 2,137 | $28K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 164 | $28K |
| 87210 | <1% | 3,251 | $26K | |
| 80164 | <1% | 1,317 | $26K | |
| 94060 | <1% | 1,002 | $25K | |
| 20553 | <1% | 463 | $25K | |
| 74018 | <1% | 2,520 | $25K | |
| 84146 | <1% | 1,363 | $24K | |
| 87040 | <1% | 3,360 | $24K | |
| 88342 | <1% | 3,216 | $24K | |
| 80143 | <1% | 1,690 | $23K | |
| 82550 | <1% | 3,493 | $23K | |
| 86704 | <1% | 2,594 | $23K | |
| 86225 | <1% | 2,147 | $22K | |
| 82570 | <1% | 5,186 | $22K | |
| 76536 | <1% | 575 | $22K | |
| 80076 | <1% | 1,882 | $21K | |
| 86706 | <1% | 2,753 | $21K | |
| 88307 | <1% | 1,756 | $21K | |
| 83001 | <1% | 1,394 | $21K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 104 | $20K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 823 | $20K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,453 | $20K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 53 | $19K |
| 82805 | <1% | 873 | $19K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,021 | $18K |
| 80179 | <1% | 1,627 | $17K | |
| 12001 | <1% | 196 | $17K | |
| 87522 | Neg quan hep c or qual rna | <1% | 553 | $17K |
| 86708 | <1% | 1,949 | $17K | |
| 84270 | <1% | 1,097 | $17K | |
| 86235 | <1% | 1,036 | $16K | |
| 93242 | <1% | 868 | $15K | |
| 73610 | <1% | 1,875 | $15K | |
| 70486 | <1% | 455 | $15K | |
| 87529 | <1% | 549 | $15K | |
| 82043 | <1% | 2,897 | $15K | |
| 82670 | <1% | 684 | $15K | |
| 86200 | <1% | 1,271 | $15K | |
| 85730 | <1% | 3,792 | $14K | |
| 87205 | <1% | 3,845 | $13K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,494 | $12K |
| 86481 | <1% | 169 | $12K | |
| 80178 | <1% | 974 | $12K | |
| 73110 | <1% | 988 | $12K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 12 | $12K |
| 73630 | <1% | 1,712 | $12K | |
| 86901 | <1% | 4,934 | $12K | |
| 93325 | <1% | 500 | $12K | |
| 0240U | <1% | 372 | $11K | |
| 93308 | <1% | 123 | $11K | |
| 72100 | <1% | 1,536 | $11K | |
| 86431 | <1% | 2,336 | $11K | |
| 83520 | <1% | 656 | $11K | |
| 82950 | <1% | 2,113 | $10K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,306 | $10K |
| 73560 | <1% | 1,713 | $10K | |
| 70491 | <1% | 116 | $10K | |
| 77066 | Tomosynthesis, mammo | <1% | 600 | $10K |
| 84132 | <1% | 1,917 | $10K | |
| 84481 | <1% | 801 | $9K | |
| 73030 | <1% | 1,440 | $9K | |
| 83525 | <1% | 997 | $9K | |
| 84156 | <1% | 2,291 | $9K | |
| 80074 | <1% | 224 | $8K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 540 | $8K |
| 84100 | <1% | 2,788 | $8K | |
| 77062 | <1% | 352 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,105 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 19,858 | $7K |
| 94726 | <1% | 1,315 | $7K | |
| 84145 | <1% | 557 | $7K | |
| 85018 | <1% | 2,205 | $7K | |
| 86709 | <1% | 801 | $7K | |
| 87484 | <1% | 277 | $6K | |
| 87468 | <1% | 277 | $6K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,279 | $6K |
| 87469 | <1% | 276 | $6K | |
| 83002 | <1% | 424 | $6K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 92 | $6K |
| 80177 | <1% | 209 | $6K | |
| 88304 | <1% | 1,922 | $6K | |
| 83721 | <1% | 755 | $6K | |
| 64493 | <1% | 27 | $6K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 76 | $5K |
| 85652 | <1% | 2,325 | $5K | |
| 62321 | <1% | 34 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 42,163 | $5K |
| 80175 | <1% | 360 | $5K | |
| 85014 | <1% | 1,401 | $5K | |
| 88720 | <1% | 56 | $4K | |
| 82553 | <1% | 996 | $4K | |
| 84550 | <1% | 1,236 | $4K | |
| 94729 | <1% | 1,555 | $4K | |
| 74019 | <1% | 299 | $4K | |
| 86376 | <1% | 386 | $4K | |
| 70496 | <1% | 73 | $4K | |
| 82010 | <1% | 677 | $4K | |
| 84480 | <1% | 371 | $4K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 3,545 | $4K |
| 76801 | <1% | 342 | $4K | |
| 83921 | <1% | 231 | $3K | |
| 74178 | <1% | 56 | $3K | |
| 82247 | <1% | 142 | $3K | |
| 82533 | <1% | 249 | $3K | |
| 90715 | <1% | 544 | $3K | |
| 73130 | <1% | 796 | $3K | |
| 93970 | <1% | 76 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 229 | $3K |
| 84144 | <1% | 135 | $3K | |
| 80069 | <1% | 378 | $3K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 123 | $3K |
| 82140 | <1% | 212 | $3K | |
| 86617 | <1% | 238 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,509 | $2K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 40 | $2K |
| 86787 | <1% | 364 | $2K | |
| 93321 | <1% | 28 | $2K | |
| 73070 | <1% | 184 | $2K | |
| 86160 | <1% | 306 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 28 | $2K |
| 87653 | <1% | 72 | $2K | |
| 85048 | <1% | 830 | $2K | |
| 73502 | <1% | 514 | $2K | |
| 12011 | <1% | 28 | $2K | |
| 76942 | <1% | 734 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 147 | $2K |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 14 | $2K |
| 97162 | <1% | 320 | $2K | |
| 86666 | <1% | 269 | $2K | |
| 0296T | <1% | 135 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 33 | $2K |
| 93976 | <1% | 43 | $2K | |
| 94770 | <1% | 57 | $2K | |
| 86255 | <1% | 97 | $2K | |
| 84165 | <1% | 202 | $2K | |
| 70498 | <1% | 28 | $2K | |
| 95811 | <1% | 15 | $1K | |
| 86696 | <1% | 66 | $1K | |
| 86003 | <1% | 259 | $1K | |
| 81015 | <1% | 498 | $1K | |
| 82977 | <1% | 271 | $1K | |
| 86800 | <1% | 116 | $1K | |
| 82627 | <1% | 71 | $1K | |
| 86364 | <1% | 141 | $1K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 26 | $1K |
| 76870 | <1% | 38 | $1K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 92 | $1K |
| 93880 | <1% | 41 | $1K | |
| 82248 | <1% | 183 | $1K | |
| 85007 | <1% | 210 | $982.60 | |
| 86695 | <1% | 66 | $950.59 | |
| 86753 | <1% | 131 | $880.15 | |
| 73590 | <1% | 62 | $873.07 | |
| 77061 | <1% | 42 | $819.42 | |
| 84155 | <1% | 208 | $780.78 | |
| 82105 | <1% | 70 | $699.60 | |
| 82947 | <1% | 143 | $672.94 | |
| 93225 | <1% | 28 | $641.94 | |
| 72040 | <1% | 12 | $637.32 | |
| 83498 | <1% | 27 | $624.95 | |
| 82150 | <1% | 98 | $545.95 | |
| 88360 | <1% | 12 | $542.04 | |
| 77080 | <1% | 16 | $534.36 | |
| 76882 | <1% | 14 | $527.50 | |
| 84425 | <1% | 25 | $469.46 | |
| 93295 | <1% | 26 | $469.01 | |
| 93922 | <1% | 15 | $457.92 | |
| 82330 | <1% | 45 | $450.06 | |
| 87147 | <1% | 112 | $438.10 | |
| 17250 | <1% | 16 | $411.54 | |
| 83993 | <1% | 25 | $409.30 | |
| 87252 | <1% | 15 | $406.65 | |
| 76937 | <1% | 133 | $405.54 | |
| 71271 | <1% | 14 | $389.78 | |
| 85045 | <1% | 143 | $381.73 | |
| 87338 | <1% | 29 | $372.01 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,852 | $345.76 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 882 | $319.71 |
| 11721 | <1% | 31 | $315.68 | |
| 93298 | <1% | 44 | $310.57 | |
| 87625 | <1% | 27 | $309.80 | |
| 83615 | <1% | 104 | $303.02 | |
| 85049 | <1% | 158 | $299.45 | |
| 93280 | <1% | 15 | $295.25 | |
| 93016 | <1% | 13 | $282.84 | |
| 87075 | <1% | 47 | $276.07 | |
| 76000 | <1% | 34 | $270.07 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,462 | $268.60 |
| 96376 | <1% | 6,517 | $259.65 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 841 | $257.82 |
| 86812 | <1% | 13 | $246.53 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 320 | $238.32 |
| 94010 | <1% | 43 | $237.06 | |
| 90686 | <1% | 40 | $223.52 | |
| 93018 | <1% | 13 | $192.51 | |
| 80197 | <1% | 19 | $182.11 | |
| 87493 | <1% | 12 | $175.48 | |
| 73140 | <1% | 84 | $161.93 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 7,847 | $161.58 |
| 82951 | <1% | 12 | $148.23 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 234 | $144.00 |
| 88302 | <1% | 94 | $137.36 | |
| 93246 | <1% | 16 | $136.23 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 91 | $128.53 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 21,258 | $126.73 |
| 36416 | <1% | 2,608 | $125.83 | |
| 82800 | <1% | 24 | $125.07 | |
| 93294 | <1% | 31 | $121.65 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,495 | $119.47 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,743 | $112.72 |
| 88173 | <1% | 53 | $104.01 | |
| 82274 | <1% | 12 | $101.88 | |
| A9270 | Non-covered item or service | <1% | 23,849 | $99.89 |
| 85613 | <1% | 16 | $99.89 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 246 | $98.32 |
| 99152 | <1% | 1,291 | $77.85 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 5,825 | $75.22 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,301 | $74.09 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,898 | $70.22 |
| 86039 | <1% | 12 | $63.54 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 14 | $62.36 |
| 84460 | <1% | 15 | $54.48 | |
| 73565 | <1% | 25 | $53.56 | |
| 36591 | <1% | 89 | $40.41 | |
| 85651 | <1% | 12 | $39.32 | |
| 73090 | <1% | 16 | $37.78 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 15,773 | $37.49 |
| J2704 | Injection, propofol, 10 mg | <1% | 16,822 | $36.12 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 446 | $34.45 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 259 | $34.37 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 16,230 | $26.12 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 786 | $20.60 |
| 72070 | <1% | 15 | $18.62 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,115 | $16.65 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 14,605 | $16.43 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 16,790 | $13.35 |
| 97161 | <1% | 13 | $11.38 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,268 | $10.90 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 14 | $10.09 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 337 | $9.80 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 23,924 | $8.85 |
| 99153 | Mod sedat endo service >5yrs | <1% | 193 | $7.64 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 486 | $7.20 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13,409 | $6.89 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,849 | $6.48 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 10,146 | $5.51 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 52 | $1.39 |
| C1769 | Guide wire | <1% | 1,971 | $0.80 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,965 | $0.80 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,096 | $0.36 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,957 | $0.31 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 247 | $0.16 |
| J3490 | Unclassified drugs | <1% | 2,667 | $0.11 |
| J1815 | Injection, insulin, per 5 units | <1% | 4,203 | $0.11 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,957 | $0.08 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 50 | $0.02 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 2,402 | $0.02 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 1,683 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,018 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 1,184 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 1,148 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 513 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,920 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 95 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 491 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 136 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 726 | $0.00 |
| A9573 | Injection, gadopiclenol, 1 ml | 0% | 35 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 3,926 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 14 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 506 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 91 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 58 | $0.00 |
| J2002 | Injection, lidocaine hcl in 5% dextrose, 1 mg | 0% | 306 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 13 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 57 | $0.00 |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 0% | 13 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 75 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 50 | $0.00 |
| G8992 | Other physical or occupational therapy primary functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 19 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 15 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 47 | $0.00 |
| 51798 | 0% | 14 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 36 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 1,626 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 896 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 2,448 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 2,061 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 170 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 2,786 | $0.00 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | 0% | 2,064 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 126 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 1,178 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 445 | $0.00 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 433 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 142 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 393 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 68 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 1,247 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 17 | $0.00 |
| 88313 | 0% | 47 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 17 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 241 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 104 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 237 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 167 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 16 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 13 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialENGEBOSE, ABBY (CREDENTIALING SPECIALIST)
| Provider | Location | Paid |
|---|---|---|
| Bellin Memorial Hospital INC | Green Bay, WI | $19.80M |
| Oconto Hospital & Medical Center INC | Marinette, WI | $4.19M |
| Bellin Memorial Hospital INC | Algoma, WI | $249K |
| Bellin Memorial Hospital INC | Kewaunee, WI | $175K |
| Bellin Memorial Hospital INC | Brillion, WI | $22K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.